Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients

• DOI: 10.1111/j.1440-1746.1990.tb01115.x
• Publication Date: 2008-03-10T22:43:27Z
• Authors: MASAAKI EBARA; MASAO OHTO; NOBUYUKI SUGIURA; KAZUHIKO KITA; MASAHARU YOSHIKAWA; KUNIO OKUDA; FUKUO KONDO; YOICHIRO KONDO
• Keywords: Percutaneous ethanol injection

Abstract Percutaneous ethanol injection (PEI) was applied to 120 lesions in 95 patients with hepatocellular carcinomas (HCC) smaller than 3 cm the past 6 years. All main target tumours, 67 who had been followed by sonography for more months after PEI, decreased size; 28 tumours (41.8%) became undetectable and have remained so until now. The 1‐, 2‐, 3‐, 4‐ 5‐year survival rates calculated Kaplan‐Meier method were 93%, 81%, 65%, 52% 28% respectively. These better those of HCC did not receive anticancer treatment ( P <0.01). Child's A or B status that C disease. Recurrence occurred areas within liver different from original lesion 34% one year, 61% two years 66% three PEI. PEI then repeated such patients.